28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
25 Mar
GEN
Der er intet mere forfriskende end den intellektuelle udfordring, man føler ved en kvalificeret deba..
17
22 Mar
VWS
Selskabet Alpha Wind Energy fra Bjerringbro har sendt en ansøgning til US Interior Department om at ..
16
23 Mar
VWS
“Apex Offshore Wind” er et datter-selskab under “Apex Wind Energy Holdings” og dette selskab har A.P..
15
21 Mar
OMXC20
Ja alle starter et sted og det er absolut ikke træls at nye investorer spørger om råd. Det er i mine..
14
26 Mar
OMXC20
Der er ingen korrektion igang, bare lidt ligegyldig panik fordi Saudi har bombet nogle oprørere i Ye..
12
21 Mar
EXQ
Hermed det lovede referat. Der blev ikke sagt SÅ meget nyt, det meste var ting man læse i årsrapport..
12
22 Mar
OMXC20
Med det beløb er 10 forskellige nok i overkanten til at starte med. Start evt. med det halve og udby..
11
24 Mar
I:DAX
Den debat du skal have her er om man skal forholde sig til virkeligheden er i dag eller hvordan den ..
10
23 Mar
 
http://npinvestor.dk/nyheder/gr%C3%A6kenland-tsipras-klager-sin-n%C3%B8d-i-brev-til-merkel   Smid de..
10
21 Mar
OMXC20
formøbleren, mobe76, USADividends og tumult; hvad mener i om Lars Tvedes udtalelse fra d. 14. marts ..
10

Tech Companies Send Criticism Along With NSA-Related Data -- Update

04/02/2014 00:06:00
By Danny Yadron Technology companies including Google Inc. and Microsoft Corp. released new figures on the amount of data requests they received from U.S. ..

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Motiva Enterprises Integrates Refineries to Create Louisiana Refining System
2
GENFIT ANNOUNCES TOPLINE RESULTS FROM THE GOLDEN-505 TRIAL IN NASH
3
Brighter AB : Clarification about Brighter & Microsoft collaboration.
4
Novo Nordisk A/S : Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US
5
PrimeSource Building Products erhöht die Geschwindigkeit der SAP-Datenbank um das Vierfache – in weniger als 24 Stunden – mithil

Copyright Euroinvestor A/S 2015   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
27 March 2015 11:55:47
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20150325.1 - EUROWEB7 - 2015-03-27 12:55:47 - 2015-03-27 11:55:47 - 1000 - Website: OKAY